On Friday, shares of BioCryst Pharmaceuticals Inc (BCRX) fell into oversold territory, registering a Relative Strength Index (RSI) of 29.6 after trading as low as $9.19 per share. In comparison, the S&P 500 ETF (SPY) has an RSI of 68.7. A lower RSI indicates potential buying opportunities as heavy selling may be exhausting.
BCRX’s 52-week low is $6.015, and its high is $11.31, with the last trade recorded at $9.36.
